First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

British Journal of Cancer

Volumn 111, Issue 2, 2014, Pages 241-248

  Feliu, J ^a   Salud, A ^b   Safont, M J ^c   Garcia Giron C ^d   Aparicio, J ^e   Vera, R ^f   Serra, O ^g   Casado, E ^h   Jorge, M ⁱ   Escudero, P ^j   Bosch, C ^k   Bohn, U ^l   Perez Carrion R ^m   Carmona, A ⁿ   Martinez Marin V ^a   Maurel, J ^o  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f Universidad Pública de Navarra   (Spain)

^g Hospital de Sant Joan Despi Moises Broggi   (Spain)

^h HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

ⁱ Complejo Hospitalario Xeral Cíes ^*  (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^l HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^m HOSPITAL QUIRÓN   (Spain)

ⁿ HOSPITAL MORALES MESEGUER   (Spain)

^o HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

bevacizumab; colorectal cancer; elderly; XELOX

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; ORGANOPLATINUM COMPOUNDS;

EID: 84904576095     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.346     Document Type: Article

References (44)

1. Abdelwahab S, Azmy A, Abdel-Aziz H, Salim H, Mahmoud A (2012) Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC). J Cancer Res Clin Oncol 138: 1487-1492.
2. Benavides M, Pericay C, Valladares-Ayerbes M, Gil-Calle S, MassutB, Aparicio J, Dueñas R, Gonza?ez-Flores E, Carrato A, Marcuello E, Go?ez A, Cabrera E, Queralt B, Go?ez MJ, Guasch I, Etxeberr A, Alfaro J, Campos JM, Reina JJ, Aranda E (2012) Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. Clin Colorectal Cancer 11: 200-206.
3. Berretta M, Cappellani A, Fiorica F, Nasti G, Frustaci S, Fisichella R, Bearz A, Talamini R, Lleshi A, Tambaro R, Cocciolo A, Ristagno M, Bolognese A, Basile F, Meneguzzo N, Berretta S, Tirelli U (2011) FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: a prospective study. Arch Gerontol Geriatr 52: 89-93.
4. Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP (2010) Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 136: 737-743.
5. Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM (2006) Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 101: 2308-2318.
6. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP. AVEX study investigators (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14: 1077-1085.
7. Daniele B, Rosati G, Tambaro R, Ottaiano A, De Maio E, Pignata S, Iaffaioli RV, Rossi A, Manzione L, Gallo C, Perrone F (2003) First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. J Clin Gastroenterol 36: 228-233.
8. Dz-Rubio E, Go?ez-España A, MassutB, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martez de Prado P, Galle? M, Gonza?ez E, Marcuello E, Benavides M, Ferna?dez-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, Lo?ez-Ladro? A, Lacasta A, Llanos M, Tabernero JM, Anto? A, Aranda E Spanish Cooperative Group for the Treatment of Digestive Tumors (2012) First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 17 15-25.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
10. Feliu J, Escudero P, Llosa F, Bolaños M, Vicent JM, Yubero A, Sanz-Lacalle JJ, Lopez R, Lopez-Go?ez L, Casado E, Go?ez-Reina MJ, Gonza?ez-Baron M (2005) Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz cooperative group study. J Clin Oncol 23: 3104-3111.
11. Feliu J, Salud A, Escudero P, Lopez-Go?ez L, Bolaños M, Gala? A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, Gonza?ez-Baro? M (2006) XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 94: 969-9675.
12. Feliu J, Safont MJ, Salud A, Losa F, Garc-Giro? C, Bosch C, Escudero P, Lo?ez R, Madroñal C, Bolaños M, Gil M, Llombart A, Castro-Carpeño J, Gonza?ez-Baro? M (2010) Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 102: 1468-1473.
13. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26: 3523-3529.
14. Hurwitz H, Mitchell EP, Cartwright T, Kwok A, Hu S, McKenna E, Patt YZ (2012) A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). Oncologist 17: 937-946.
15. Jessup JM, Stewart A, Greene FL, Minsky BD (2005) Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294: 2758-2760.
16. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365: 217-223.
17. Khattak MA, Townsend AR, Beeke C, Karapetis CS, Luke C, Padbury R, Maddern G, Roder D, Price TJ (2012) Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. Eur J Cancer 48: 1293-1298.
18. Koopman M, Simkens LHJ, Ten Tije AJ, Creemers G-J, Loosveld OJL, de Jongh FE, Erdkamp F, Erjavec Z, van der Torren AME, Van der Hoeven JJM, Nieboer P, Braun JJ, Jansen RL, Haasjes JG, Cats A, Wals JJ, Mol L, Dalesio O, van Tinteren H, CJA Punt (2013) Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 31(suppl): abstr 3502.
19. Lemmens VEPP, van Halteren AH, Janssen-Heijnen ML, Vreugdenhil G, Repelaer van Driel OJ, Coebergh JW (2005) Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender and comorbidity. Ann Oncol 16: 767-772.
20. Lionakis N, Mendrinos D, Sanidas E, Favatas G, Georgopoulou M (2012) Hypertension in the elderly. World J Cardiol 4: 135-147.
21. Mattioli R, Massacesi C, Recchia F, Marcucci F, Cappelletti C, Imperatori L, Pilone A, Rocchi M, Cesta A, Laici G, Bonsignori M, Lippe P (2005) High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 16: 1147-1151.
22. McKibbin T, Frei CR, Greene RE, Kwan P, Simon J, Koeller JM (2008) Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist 13: 876-885.
23. Morris M, Platell C, Fritschi L, Iacopetta B (2007) Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer 96: 701-707.
24. Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC (2012) Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol 23: 1531-1536.
25. Puthillath A, Mashtare Jr T, Wilding G, Khushalani N, Steinbrenner L, Ross ME, Romano K, Wisniewski M, Fakih MG (2009) A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. Crit Rev Oncol Hematol 71: 242-248.
26. Rosati G, Cordio S, Tucci A, Blanco G, Bordonaro R, Reggiardo G, Manzione L (2005) Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology 69: 122-129.
27. Rosati G, Cordio S, Bordonaro R, Caputo G, Novello G, Reggiardo G, Manzione L (2010) Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann Oncol 21: 781-786.
28. Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D (2013) XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol 71: 257-264.
29. Saltz LB, Clarke S, Dz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirze? F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019.
30. Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Anto A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, Dz-Rubio E. Cooperative Group for the Treatment of Digestive Tumors (2005) Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 23: 3545-3551.
31. Sastre J, Aranda E, MassutB, Tabernero J, Chaves M, Abad A, Carrato A, Reina JJ, Queralt B, Goez-Espana A, Gonzaez-Flores E, Rivera F, Losa F, Garc T, Sanchez-Rovira P, Maestu I, Dz-Rubio E (2009) Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol 70: 134-144.
32. Sastre J, Aranda E, Graalos C, MassutB, Varella-Garcia M, Rivera F, Soler G, Carrato A, Manzano JL, Dz-Rubio E, Hidalgo M (2011) First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 77: 78-84.
33. Sastre J, Graalos C, Rivera F, Massuti B, Valladares-Ayerbes M, Marcuello E, Manzano JL, Benavides M, Hidalgo M, Dz-Rubio E, Aranda E (2012) First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist 17: 339-345.
34. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232-1239.
35. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kone CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23: 2479-2516.
36. Sorbye H, Pfeiffer P, Cavalli-Bjokman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, Glimelius B (2009) Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 115: 4679-4687.
37. Souglakos J, Pallis A, Kakolyris S, Mavroudis D, Androulakis N, Kouroussis C, Agelaki S, Xenidis N, Milaki G, Georgoulias V (2005) Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 69: 384-390.
38. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ (2010) Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28: 3191-3198.
39. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, AndreT, Tabah-Fisch I, de Gramont A (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24: 394-400.
40. Tsutsumi S, Yamaguchi S, Tsuboi K, Fukasawa T, Yamaki S, Asao T, Kuwano H (2006) Oral regimen consisting of UFT/UZEL for elderly patients with colorectal cancer. Hepatogastroenterology 53: 209-212.
41. Vamvakas L, Athanasiadis A, Karampeazis A, Kakolyris S, Polyzos A, Ch Kouroussis, Ziras N, Kalbakis K, Georgoulias V, Souglakos J (2010) Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). Crit Rev Oncol Hematol 76: 61-70.
42. Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJ, Koopman M (2012) Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol 51: 831-839.
43. Vrdoljak E, Omrcien T, Boban M, Hrabar A (2011) Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer. Anticancer Drugs 22: 191-197.
44. Wong NS, Fernando NH, Nixon AB, Cushman S, Aklilu M, Bendell JC, Morse MA, Blobe GC, Ashton J, Pang H, Hurwitz HI (2011) A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res 31: 255-261.